ADAG Adagene Inc. Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1818838 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY7,332.8%
TTM net income YoY47.3%
TTM EPS YoY49.2%
Revenue 3-yr CAGR-6.2%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-279.5%
Net margin-229.6%
FCF margin-204.3%
EBITDA margin-273.8%
Returns
ROE-41.0%
ROA-21.0%
ROIC (approx.)—
Asset turnover0.09x
Leverage & solvency
Liabilities / assets33.7%
Debt / equity0.17x
Current ratio3.07x
Interest coverage-46.29x
Cash quality & payout
Operating cash flow / net income0.89x
Accruals ratio-2.3%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $7.67M | $103,204 | $18.11M | $9.29M | $10.18M |
| R&D expense | $22.03M | $28.78M | $36.64M | $81.34M | $68.10M |
| SG&A expense | $7.08M | $7.27M | $8.67M | $11.87M | $14.44M |
| Operating income | -$21.44M | -$35.95M | -$23.72M | -$83.92M | -$72.36M |
| Interest expense | $463,132 | $851,874 | $1.11M | $693,323 | $363,762 |
| Pretax income | -$17.91M | -$33.44M | -$17.25M | -$79.51M | -$71.48M |
| Income tax | -$297,860 | -$17,553 | $1.69M | $459,055 | $1.70M |
| Net income | -$17.61M | -$33.42M | -$18.95M | -$79.97M | -$73.18M |
| EBITDA | -$21.00M | -$35.23M | -$22.74M | -$82.77M | -$71.24M |
| EPS (basic) | -0.30 | -0.59 | -0.35 | -1.48 | -1.46 |
| EPS (diluted) | -0.30 | -0.59 | -0.35 | -1.48 | -1.46 |
| Weighted avg. shares (diluted) | 59.01M | 56.29M | 54.74M | 54.14M | 50.03M |
| Balance sheet | |||||
| Cash & equivalents | $74.52M | $85.19M | $109.93M | $143.76M | $174.39M |
| Short-term investments | $0 | $0 | $0 | — | — |
| Receivables | — | — | — | — | $3.00M |
| Current assets | $77.38M | $87.78M | $113.44M | $149.32M | $185.95M |
| PP&E, net | $717,374 | $1.13M | $1.84M | $2.78M | $3.49M |
| Total assets | $78.26M | $89.27M | $115.73M | $152.40M | $189.51M |
| Current liabilities | $25.17M | $38.18M | $31.46M | $55.08M | $29.82M |
| Short-term debt | $4.98M | $17.79M | $8.40M | $13.62M | $4.50M |
| Long-term debt | $1.14M | $417,339 | $13.54M | $14.15M | $2.99M |
| Total debt | $6.12M | $18.21M | $21.94M | $27.77M | $7.49M |
| Total liabilities | $26.36M | $38.74M | $45.17M | $69.31M | $32.95M |
| Shareholders' equity | $35.35M | $50.52M | $70.56M | $83.09M | $156.56M |
| Net debt | -$68.41M | -$66.98M | -$88.00M | -$115.99M | -$166.90M |
| Shares outstanding | 59.23M | 58.89M | 55.15M | 54.07M | 54.60M |
| Cash flow statement | |||||
| Operating cash flow | -$15.66M | -$29.70M | -$28.45M | -$48.61M | -$43.41M |
| Capital expenditure | $17,053 | $33,580 | $85,012 | $690,938 | $2.51M |
| Free cash flow | -$15.67M | -$29.73M | -$28.54M | -$49.30M | -$45.92M |
| Investing cash flow | $476,803 | $1.11M | -$77,356 | -$686,046 | -$2.51M |
| Financing cash flow | $4.45M | $3.77M | -$5.37M | $17.82M | $145.36M |
| Depreciation & amortization | $438,864 | $722,950 | $980,053 | $1.15M | $1.13M |
| Stock-based compensation | $3.74M | $4.91M | $7.27M | $10.52M | $18.68M |
| Share buybacks | — | — | — | $3.98M | $2.36M |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.